pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
BioNTech SE projects
11 ClinicalTrials.gov programs sponsored by BioNTech SE.
BioNTech SE has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BNT111-01
BioNTech SE
Melanoma (Stage III and IV)
1 trial -
BNT142
BioNTech SE
Solid Tumors
1 trial -
BNT314-02
BioNTech SE
Metastatic colorectal cancer
1 trial -
BNT321-02
BioNTech SE
Resected (R0 or R1) pancreatic ductal adenocarcinoma
1 trial -
BNT326-01
BioNTech SE
Advanced solid tumors
1 trial -
BNT326-02
BioNTech SE
Non-small Cell Lung Cancer
1 trial -
BNT327, BNT323
BioNTech SE
Advanced Breast Cancer Metastatic Breast Cancer
1 trial -
BNT327, BNT324
BioNTech SE
Advanced Lung Cancer
1 trial -
BNT327, DOCETAXEL
BioNTech SE
Non-small Cell Lung Cancer
1 trial -
BNT329
BioNTech SE
Advanced Solid Cancers
1 trial -
Watchful waiting, RO7198457 (autogene cevumeran)
BioNTech SE
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer
1 trial
Frequently asked questions
How many clinical projects does BioNTech SE have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.